ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $6.03M, a 274.29% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $5.13M, a 5.83% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $9.04M, a 7018.90% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.78M, a 4342.50% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for fiscal 2025 was $17.88M, a 7318.67% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for fiscal 2024 was $241.00K, a 89.27% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for fiscal 2023 was $2.25M, a 71.46% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION stock issued during period, value, stock options exercised for fiscal 2022 was $7.87M, a 70.30% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $6.03M 10-Q · filed 2026-08-04 | $21.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $5.13M 10-Q · filed 2026-05-05 | $17.56M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.88M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.78M 10-Q · filed 2025-11-05 | $8.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.61M 10-Q · filed 2026-08-04 | $7.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $5.45M 10-Q · filed 2026-05-05 | $5.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $241.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.00K 10-Q · filed 2025-11-05 | $201.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.00K 10-Q · filed 2025-08-05 | $178.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $44.00K 10-Q · filed 2025-05-01 | $1.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.25M 10-K · filed 2026-02-26 |
| 2023-09-30 | $17.00K 10-Q · filed 2024-11-07 | $2.46M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.47M 10-Q · filed 2024-08-01 | $3.29M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $672.00K 10-Q · filed 2024-05-07 | $5.80M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $7.87M 10-K · filed 2025-03-03 |
| 2022-09-30 | $846.00K 10-Q · filed 2023-11-09 | $10.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.98M 10-Q · filed 2023-08-02 | $12.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.73M 10-Q · filed 2023-05-03 | $14.78M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $26.48M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.80M 10-Q · filed 2022-11-03 | $29.38M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $6.06M 10-Q · filed 2022-08-03 | $30.83M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $14.44M 10-Q · filed 2022-05-04 | $31.46M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $21.54M 10-K · filed 2023-02-14 |
| 2020-09-30 | $4.24M 10-Q · filed 2021-11-03 | $17.67M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $6.70M 10-Q · filed 2021-08-04 | $13.75M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $4.52M 10-Q · filed 2021-05-05 | $8.90M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.41M 10-K · filed 2022-02-15 |
| 2019-09-30 | $318.00K 10-Q · filed 2020-11-10 | $2.48M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.85M 10-Q · filed 2020-08-10 | $2.23M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $33.00K 10-Q · filed 2020-05-12 | $793.00K derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.17M 10-K · filed 2021-02-24 |
| 2018-09-30 | $62.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $415.00K 10-Q · filed 2019-08-13 | |
| 2017-12-31 | $95.00K 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |